Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
AssigneeInstitut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsVanessa Deveaux, Fatima Teixeira Clerc, Sylvie Manin, Sophie Lotersztajn, Ariane Mallat, Jeanne Tran-Van-Nhieu
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for treating and/or preventing obesity and/or obesity-related disorders by administering to a subject in need thereof a selective inhibitor of cannabinoid type 2 (CB2) receptor expression.
Claims4
A method for treating and/or preventing insulin resistance comprising administering to a subject in need thereof a selective inhibitor of cannabinoid type 2 (CB2) receptor expression, wherein said inhibitor of CB2 receptor expression is selected from the group consisting of antisense RNA or DNA molecules, small inhibitory RNAs (SiRNAs) and ribozymes.
Dependencies are inferred from the claim text.